The new NIH and FDA medical research policies: Targeting gender, promoting justice

Journal of Health Politics, Policy and Law

Volumn 24, Issue 3, 1999, Pages 531-565

  Baird, Karen L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; MEDICAL RESEARCH; POLITICS; REVIEW; SEX ROLE;

EID: 0032996699     PISSN: 03616878     EISSN: None     Source Type: Journal    
DOI: 10.1215/03616878-24-3-531     Document Type: Review

References (45)

1. Auerbach, J. D. 1992. The Emergence of the Women's Health Research Agenda: Some Preliminary Analysis. Paper presented at the annual meeting of the Association for Public Policy Analysis and Management, Denver, CO, 29-31 October.
2. Baird, K. 1998a. Gender Justice and the Health Care System. New York: Garland.
3. _. 1998b. The NIH and FDA New Medical Research Policies: A Case of Policy Streams or Advocacy Coalitions? Paper delivered at the 1998 annual meeting of the American Political Science Association, Boston, 3-6 September.
4. Bartlett, K. T., and R. Kennedy, eds. 1991. Feminist Legal Theory. Boulder, CO: West-view.
5. Berney, B. 1990. In Research, Women Don't Matter. The Progressive, October, 24-27.
6. Commonwealth Fund. 1993. The Commonwealth Fund Survey of Women's Health. New York: The Commonwealth Fund, 14 July.
7. Dresser, R. 1992. Wanted: Single, White Male for Medical Research. Hastings Center Report, January-February, 24-29.
8. Fraser, N. 1994. After the Family Wage: Gender Equity and the Welfare State. Political Theory 22(4):591-618.
9. Freedman, L., R. Simon, M. Foulkes, L. Friedman, N. Geller, D. Gordon, and R. Mowery. 1995. Response to Discussants' Letters. Controlled Clinical Trials 16:310-312.
10. Goldzieher, J. W., L. Moses, E. Averkin, C. Scheel, and B. Taber. 1971a. A Placebo-Controlled Double-Blind Crossover Investigation of the Side Effects Attributed to Oral Contraceptives. Fertility and Sterility 22(9):609-623.
11. _. 1971b. Nervousness and Depression Attributed to Oral Contraceptives: A Double-Blind, Placebo-Controlled Study. American Journal of Obstetrics and Gynecology 22:1013-1020.
12. Hayunga, E. 1996. Implementation of Inclusion Guidelines. From a workshop on the NIH inclusion guidelines, Office of Research on Women's Health (ORWH), 22 February. Bethesda, MD: Office of Research on Women's Health.
13. Hayunga, E., M. D. Costello, and V. Pinn. 1997. Demographics of Study Populations. Applied Clinical Trials 6(1):41-45.
14. Institute of Medicine (IOM), Division of Health Sciences Policy, Committee on the Ethical and Legal Issues Relating to the Inclusion of Women in Clinical Studies. 1994. Women and Health Research, Volumes 1 and 2, ed. A. Mastroianni, R. Faden, and D. Federman. Washington, DC: National Academy.
15. Jaschik, S. 1990. Report Says NIH Ignores Own Rules on Including Women in its Research. Chronicle of Higher Education, 27 June, A27.
16. Johnson, T., and E. Fee. 1994. Women's Participation in Clinical Research: From Protectionism to Access. In Women and Health Research, Volume 2, ed. Anna Mastroianni, Ruth Faden, and Daniel Federman. Washington, DC: National Academy.
17. Jones, J. 1981. Bad Blood: The Tuskegee Syphilis Experiment. New York: Free Press.
18. Kadar, A. 1994. The Sex Bias in Medicine. Atlantic Monthly 274(2):66-71.
19. Kinney, E. L. 1981. Underrepresentation of Women in New Drug Trials: Ramifications and Remedies. Annals of Internal Medicine 95(4):495-499.
20. LaRosa, J., B. Seto, C. Caban, and E. Hayunga. 1995. Including Women and Minorities in Clinical Research. Applied Clinical Trials 4:31-38.
21. Littleton, C. A. 1987. Reconstructing Sexual Equality. California Law Review 75(4):1279-1337.
22. Moreno, J. D. 1994. Ethical Issues Related to the Inclusion of Women of Childbearing Age in Clinical Trials. In Women and Health Research, Volume 2, ed. A. Mastroianni, R. Faden, and D. Federman. Washington, DC: National Academy Press.
23. Nussbaum, M. 1995. Human Capabilities, Female Human Beings. In Women, Culture, and Development, ed. M. Nussbaum and J. Glover. New York: Clarendon.
24. Nussbaum, M., and J. Glover, eds. 1995. Women, Culture, and Development. New York: Clarendon.
25. Primmer, L. 1998. Interview with author, Washington, DC, 26 March.
26. Rhode, D. L. 1989. Justice and Gender. Cambridge: Harvard University Press.
27. Rothenberg, K. 1996. Gender Matters: Implications for Clinical Research and Women in Health Care. Houston Law Review 32(5):1201-1272.
28. Schroeder, P., and O. Snowe. 1994. The Politics of Women's Health. In The American Woman 1994-95, ed. C. Costello and A. Stone. New York: Norton.
29. Simons, M. 1996. UN Court, for First Time, Defines Rape as War Crime. New York Times, 28 June, A1.
30. Thomas, S. 1994. How Women Legislate. New York: Oxford University Press.
31. Tong, R. 1989. Feminist Thought. Boulder, CO: Westview.
32. U.S. Congress. House. Subcommittee on Housing and Consumer Interests. Select Committee on Aging. 1990. Women Health Care Consumers: Shortchanged on Medical Research and Treatment. 101st Cong., 2d sess., 24 July.
33. U.S. Department of Health and Human Services (U.S. DHHS), Food and Drug Administration (FDA). 1988. Guideline for the Format and Content of the Clinical and Statistical Sections of New Drug Applications. Washington, DC: U.S. Department of Health and Human Services.
34. _. 1993. Guideline for the Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs. Federal Register 58(139):39406-39416.
35. U.S. Department of Health and Human Services (U.S. DHHS), National Institutes of Health (NIH). 1994a. NIH Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research. Federal Register 59(59):14508-14513.
36. _. 1994b. Outreach Notebook for the NIH Guidelines on Inclusion of Women and Minorities as Subjects in Clinical Research. Bethesda, MD: National Institutes of Health.
37. U.S. Department of Health, Education, and Welfare (U.S. DHEW), Public Health Service, Food and Drug Administration (FDA). 1977. General Considerations for the Clinical Evaluation of Drugs. Washington, DC: U.S. Government Printing Office, HEW/FDA-77-3040.
38. U.S. General Accounting Office (U.S. GAO). 1990. National Institutes of Health: Problems in Implementing Policy on Women in Study Populations. Testimony of Mark Nadel before the Subcommittee on Health and the Environment, Committee on Energy and Commerce, House of Representatives. 101st Cong., 2d sess., 18 June.
39. _. 1992. Women's Health: FDA Needs to Ensure More Study of Gender Differences in Prescription Drug Testing. Washington, DC: U.S. Government Printing Office, GAO/HRD-93-17.
40. Weisman, C. S. 1998. Women's Health Care: Activist Traditions and Institutional Change. Baltimore, MD: Johns Hopkins University Press.
41. Wierenga, D. E., and C. Eaton. 1993. The Drug Development and Approval Process. In In Development: New Medicines for Older Americans. Washington, DC: Pharmaceutical Manufacturers Association.
42. Wolgast, E. H. 1980. Equality and the Rights of Women. Ithaca, NY: Cornell University Press.
43. Woolson, R., M. Jones, W. Clarke, and J. Torner. 1995. Discussion of "Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1993-The Perspective of NIH Clinical Trialists." Controlled Clinical Trials 16:301-333.
44. Young, I. M. 1990. Justice and the Politics of Difference. Princeton, NJ: Princeton University Press.
45. Zimmerman, B., et al. 1980. People's Science. In Science and Liberation, ed. R. Aditta and S. Cavarak. Montreal: South End.